Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 12/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943333 | 0.86 | CTSC (0.42) | DPP4CTSC | |
| SCHEMBL6558952 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL4638730 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL27601749 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL9797953 | 0.84 | DPP4 (0.38) | TERTDPP4DPP8DPP9DPP7 | |
| SCHEMBL9797959 | 0.84 | DPP4 (0.38) | TERTDPP4DPP8DPP9DPP7 | |
| SCHEMBL8755581 | 0.81 | — | — | |
| SCHEMBL1796260 | 0.81 | DPP4 (0.42) | DPP4DPP8SLC7A5DPP7 | |
| SCHEMBL4095830 | 0.81 | DPP4 (0.35) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL10727454 | 0.80 | PLG (0.38) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | TERT 3788/4885DPP4 525/4885DPP8 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.